Matthew B Palmer Selected Research

Matthew B Palmer Research Topics

Disease

9	Neoplasms (Cancer) 07/2021 - 12/2011
4	Proteinuria 07/2021 - 01/2016
3	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021 - 07/2014
3	Chronic Kidney Failure (Chronic Renal Failure) 11/2020 - 04/2015
3	Prostatic Neoplasms (Prostate Cancer) 04/2013 - 10/2003
2	Hypertension (High Blood Pressure) 11/2021 - 07/2021
2	Thrombotic Microangiopathies 07/2021 - 01/2016
2	Amyloidosis 01/2019 - 04/2015
2	Glomerulonephritis 01/2018 - 05/2017
2	Neoplasm Metastasis (Metastasis) 11/2014 - 11/2012
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2014 - 10/2013
2	Esophageal Neoplasms (Esophageal Cancer) 01/2012 - 12/2011
1	Ischemia 11/2022
1	renal Oncocytoma 05/2022
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2022
1	Diabetes Mellitus 11/2021
1	Albuminuria 10/2021
1	Bites and Stings (Sting) 10/2021
1	Kidney Diseases (Kidney Disease) 10/2021
1	Atypical Hemolytic Uremic Syndrome 07/2021
1	Lipoid Nephrosis (Glomerulonephritis, Minimal Change) 01/2021
1	Hodgkin Disease (Hodgkin's Disease) 12/2019
1	Interstitial Nephritis (Tubulointerstitial Nephritis) 12/2019
1	Primary Myelofibrosis (Myelosclerosis) 01/2019
1	Thrombosis (Thrombus) 01/2019
1	Vasculitis (Vasculitides) 05/2017
1	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 01/2017
1	Nephritis 01/2017
1	Infections 01/2017
1	Multiple Myeloma 01/2016
1	Radiation-Induced Neoplasms (Neoplasms, Radiation Induced) 08/2014
1	Medulloblastoma 08/2014
1	Rectal Neoplasms (Rectal Cancer) 06/2011
1	Carcinoma (Carcinomatosis) 06/2011
1	Melanoma (Melanoma, Malignant) 07/2007

Drug/Important Bio-Agent (IBA)

2	InterferonsIBA 10/2021 - 05/2017
2	LigandsIBA 07/2021 - 01/2017
2	Antiviral Agents (Antivirals)IBA 05/2017 - 01/2017
2	Proteins (Proteins, Gene)FDA Link 01/2016 - 04/2015
2	CreatinineIBA 01/2016 - 04/2015
2	Protons (Proton)IBA 08/2014 - 04/2013
1	CytokinesIBA 11/2022
1	Chemotactic FactorsIBA 11/2022
1	Succinate Dehydrogenase (Fumarate Reductase)IBA 05/2022
1	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 10/2021
1	Apolipoprotein L1IBA 10/2021
1	Disulfiram (Antabuse)FDA Link 10/2021
1	NucleotidesIBA 10/2021
1	InflammasomesIBA 10/2021
1	Angiogenesis InhibitorsIBA 07/2021
1	Monoclonal AntibodiesIBA 07/2021
1	eculizumab FDA Link 07/2021
1	Bevacizumab (Avastin)FDA Link 07/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2021
1	SilverIBA 01/2021
1	Hematoxylin (Haematoxylon)IBA 01/2021
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2021
1	Periodic AcidIBA 01/2021
1	Lenalidomide (CC 5013)FDA Link 12/2019
1	A-factor (Streptomyces)IBA 01/2019
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2019
1	ruxolitinibIBA 01/2019
1	Complement System Proteins (Complement)IBA 01/2019
1	Complement Factor H (Factor H)IBA 01/2019
1	Immunoglobulins (Immunoglobulin)IBA 01/2018
1	Antigen-Antibody Complex (Immune Complex)IBA 01/2017
1	2'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA 01/2016
1	carfilzomibIBA 01/2016
1	Proteasome InhibitorsIBA 01/2016
1	Bortezomib (Velcade)FDA Link 01/2016
1	Amyloidogenic ProteinsIBA 04/2015
1	Amyloid (Amyloid Fibrils)IBA 04/2015
1	ChromatinIBA 07/2007
1	DNA Transposable Elements (Element, IS)IBA 07/2007

Therapy/Procedure

9	Proton Therapy 01/2021 - 12/2011
7	Radiotherapy 01/2021 - 06/2011
4	Therapeutics 05/2017 - 12/2011
2	Nephrectomy 11/2021 - 11/2020
2	Re-Irradiation 11/2014 - 10/2013
1	Conformal Radiotherapy 01/2012
1	Chemoradiotherapy 12/2011
1	Brachytherapy 10/2003